1. Home
  2. IMRX vs VRXA Comparison

IMRX vs VRXA Comparison

Compare IMRX & VRXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immuneering Corporation

IMRX

Immuneering Corporation

HOLD

Current Price

$4.44

Market Cap

313.8M

Sector

Health Care

ML Signal

HOLD

VRXA

Veraxa Biotech AG Ordinary Shares

N/A

Current Price

$1.52

Market Cap

263.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMRX
VRXA
Founded
2008
N/A
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
313.8M
263.0M
IPO Year
2021
2025

Fundamental Metrics

Financial Performance
Metric
IMRX
VRXA
Price
$4.44
$1.52
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$17.20
N/A
AVG Volume (30 Days)
613.9K
395.0K
Earning Date
05-04-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
37.75
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.86
$1.27
52 Week High
$10.08
$4.50

Technical Indicators

Market Signals
Indicator
IMRX
VRXA
Relative Strength Index (RSI) 35.69 43.83
Support Level $3.98 $1.27
Resistance Level $5.32 $1.99
Average True Range (ATR) 0.22 0.20
MACD -0.10 0.04
Stochastic Oscillator 7.79 51.43

Price Performance

Historical Comparison
IMRX
VRXA

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

About VRXA Veraxa Biotech AG Ordinary Shares

Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.

Share on Social Networks: